Psychedelics Fundraising: Active Investors & FDA Playbook

How to raise venture capital for a psychedelic medicine, ketamine clinic, or psilocybin / MDMA developer in 2026.

How to Raise Venture Capital for a Psychedelics Startup

Psychedelics — Compass Pathways (Nasdaq COMP, psilocybin COMP360 for TRD), atai Life Sciences (Nasdaq ATAI, Peter Thiel-backed platform), Lykos Therapeutics (formerly MAPS PBC — FDA rejected MDMA-assisted therapy August 2024), Cybin (Nasdaq CYBN, DMT + psilocybin), MindMed (Nasdaq MNMD, LSD + MDMA), Beckley Psytech (Sun Pharma partnership), Delix Therapeutics (non-hallucinogenic analogs), GH Research (5-MeO-DMT), Reunion Neuroscience, Filament Health, plus ketamine clinics (Field Trip Health bankruptcy 2023, Mindbloom, Nue Life, Better U, Ketamine Wellness Centers bankruptcy 2023) and infrastructure (Numinus, ATMA CenterPoint) — spans FDA drug development, clinic operations, and Oregon Measure 109 + Colorado Prop 122 + Australia state-authorized therapy programs.

Why psychedelics is a distinct fundraising category

Psychedelics investors underwrite Schedule I DEA constraints on research (Schedule I substances require DEA Schedule I registration for possession, manufacture, and research — 6-24 month approval cycles), the post-Lykos FDA rejection reality (FDA rejected Lykos MDMA-assisted therapy in August 2024 citing trial design + blinding + expectancy effects — reset the entire drug-development category and forced re-underwriting of every psychedelics IND), state-level authorized programs (Oregon Measure 109 psilocybin services since 2023, Colorado Prop 122 natural medicine since 2023, Australia TGA authorized-prescriber MDMA + psilocybin since July 2023), and the ketamine-clinic collapse (Field Trip Health CCAA bankruptcy 2023, Ketamine Wellness Centers bankruptcy 2023) as cautionary reference for clinic-model unit economics.

The most active psychedelics VCs

Psychedelics-focused funds + investors: Christian Angermayer's Apeiron Investment Group (largest single backer via atai + Compass adjacencies), Peter Thiel (atai + Founders Fund adjacencies + Compass early), Kevin O'Leary (public participation), Bail Capital, PsyMed Ventures (Dina Burkitbayeva + Greg Kubin), Palo Santo, Iter Investments, Conscious Fund, Neo Kuma Ventures, Negev Capital, Vine Ventures (Ryan Zurrer), Tabula Rasa Ventures, Empath Ventures, Satori Neuro, plus family offices + HNW psychedelics angels (Bob Parsons via YAM Worldwide, Rick Doblin MAPS network).

Multi-stage generalists active in psychedelics: Founders Fund (atai + Compass adjacencies via Thiel), a16z Bio+Health (selective drug-dev deals), ARCH Venture Partners (biotech-only crossover), Casdin Capital, Perceptive Advisors (drug-dev hedge fund + PIPE), RA Capital, RTW Investments, Deerfield Management, plus Sun Pharma (Beckley Psytech partnership) and Otsuka (Compass partnership 2024) as pharma strategics.

Strategic capital + acquirers: Pharma majors have historically avoided (Schedule I, reputational + regulatory risk) but Otsuka / Compass partnership 2024 and Sun Pharma / Beckley Psytech partnership 2023 mark shift. Post-approval acquirers could include Johnson & Johnson (Spravato / esketamine for TRD already approved 2019 — precedent), Otsuka, Sun Pharma, Neurocrine, Sage Therapeutics (Zurzuvae postpartum depression 2023), Axsome Therapeutics, plus specialty psychiatric strategics.

The post-Lykos FDA rejection reality

FDA issued Complete Response Letter to Lykos Therapeutics (formerly MAPS PBC) for MDMA-assisted therapy for PTSD in August 2024 citing trial design issues, functional unblinding, expectancy effects, and additional Phase 3 requirement. The FDA advisory committee had voted 9-2 against efficacy and 10-1 against risk-benefit in June 2024. This was the most-anticipated psychedelic drug approval in decades.

Immediate impact: Lykos laid off 75% of staff August 2024, Rick Doblin resigned September 2024, additional Phase 3 trial planned but timeline + funding uncertain. Category-wide impact: every psychedelic IND now faces heightened FDA scrutiny on blinding + expectancy design.

Compass Pathways COMP360 psilocybin Phase 3 for TRD (topline 2025-2026) is now the closest-to-approval catalyst. atai / Beckley Psytech BPL-003 (5-MeO-DMT for TRD), Cybin CYB003 (deuterated psilocybin), and MindMed MM120 (LSD for GAD, Phase 3 initiated 2024) are next major FDA readouts.

Investors underwrite Lykos-post reality: heightened FDA scrutiny, single-trial approval unlikely, functional-unblinding mitigation required in trial design, and REMS + provider-training infrastructure planning from Phase 2.

Schedule I DEA constraints on research

Psychedelic substances (psilocybin, MDMA, LSD, DMT, mescaline, ibogaine) are Schedule I under the Controlled Substances Act. Schedule I research requires DEA Schedule I registration (6-24 month approval), DEA-approved supplier (limited — NIDA + specialty manufacturers), Schedule I-registered storage + chain-of-custody, and typically an FDA IND. Ketamine is Schedule III (Spravato / esketamine FDA-approved 2019) and does NOT face Schedule I constraints — this is why ketamine clinics scaled first. Investors expect explicit DEA + FDA regulatory pathway planning, not vague 'we'll figure out the regulatory later' language.

State-level authorized programs

Oregon Measure 109 (passed 2020, service delivery since January 2023): psilocybin services at licensed centers with trained facilitators, no medical indication requirement, out-of-pocket only ($1,500-3,500 per session). ~30 licensed service centers as of 2024-2025. Slower adoption than projected.

Colorado Prop 122 (passed 2022, natural medicine health-hub program launched 2024-2025): psilocybin + other natural medicines at Colorado-licensed healing centers.

Australia TGA authorized prescriber pathway (world-first since July 2023): MDMA for PTSD + psilocybin for TRD prescribed by TGA-authorized psychiatrists. High provider bar (Section 19 authorized prescriber approval) + high patient cost (AUD $10,000-25,000 per treatment course).

State-level programs are viable near-term revenue but NOT a substitute for FDA drug approval — they are lower scale, cash-pay only, and limited to specific jurisdictions.

Ketamine-clinic collapse as cautionary reference

Field Trip Health filed CCAA bankruptcy protection in Canada (2023), Ketamine Wellness Centers Chapter 11 (2023), Mindbloom raised down-round + pivoted, Nue Life pivoted. Ketamine-clinic unit economics broke on: high real-estate + clinician cost per session, low session frequency (2-6 sessions per patient), insurance-coverage friction (most self-pay), and competition from at-home ketamine (Mindbloom, Better U, Peak). Investors underwrite psychedelics-clinic models with skepticism post-2023 — model unit economics conservatively with high clinician cost + realistic session frequency.

Common mistakes when raising for psychedelics

Modeling FDA approval as base case post-Lykos rejection. Ignoring functional-unblinding + expectancy-effect trial design. Not planning REMS + provider-training infrastructure from Phase 2. Confusing ketamine (Schedule III, FDA-approved as Spravato 2019) with Schedule I psychedelics (psilocybin, MDMA, LSD, DMT). Modeling state-level programs (Oregon, Colorado, Australia) as substitute for FDA approval. Underestimating Schedule I DEA registration timeline (6-24 months). Assuming pharma strategic acquisition pre-approval — Otsuka / Compass and Sun / Beckley partnerships 2023-2024 are partnership not acquisition. Ignoring ketamine-clinic collapse (Field Trip + KWC bankruptcy 2023) in clinic-model decks.

Frequently asked questions

Which are the most active psychedelics VCs in 2026?
Christian Angermayer's Apeiron Investment Group is the largest single backer via atai Life Sciences and Compass Pathways. Peter Thiel is an early Compass and atai backer via Founders Fund adjacencies. Kevin O'Leary participates publicly. Psychedelics-focused funds include Bail Capital, PsyMed Ventures (Dina Burkitbayeva and Greg Kubin), Palo Santo, Iter Investments, Conscious Fund, Neo Kuma Ventures, Negev Capital, Vine Ventures (Ryan Zurrer), Tabula Rasa Ventures, and Empath Ventures. Biotech crossover investors active in psychedelics include ARCH Venture Partners (selective), Casdin Capital, Perceptive Advisors, RA Capital, RTW Investments, and Deerfield Management. Pharma partners include Otsuka (Compass partnership 2024) and Sun Pharma (Beckley Psytech partnership 2023). Post-approval acquirer set likely includes Johnson & Johnson (Spravato / esketamine 2019 precedent), Otsuka, Sun Pharma, Neurocrine, Sage Therapeutics, and Axsome Therapeutics.
How did the Lykos FDA rejection change psychedelics fundraising?
The FDA issued a Complete Response Letter to Lykos Therapeutics (formerly MAPS PBC) for MDMA-assisted therapy for PTSD in August 2024, citing trial design issues, functional unblinding, expectancy effects, and requiring an additional Phase 3 trial. The FDA advisory committee had voted 9-2 against efficacy and 10-1 against risk-benefit in June 2024. Lykos laid off 75% of staff in August 2024 and Rick Doblin resigned in September 2024. Category-wide, every psychedelic IND now faces heightened FDA scrutiny on blinding and expectancy design. Investors underwrite Lykos-post reality: single-trial approval is unlikely, functional-unblinding mitigation is required (active placebo, blinded assessor design), and REMS plus provider-training infrastructure must be planned from Phase 2. Compass Pathways COMP360 psilocybin Phase 3 for TRD (topline 2025-2026) is the closest-to-approval catalyst.
What Schedule I DEA constraints apply to psychedelics research?
Psychedelic substances (psilocybin, MDMA, LSD, DMT, mescaline, ibogaine) are Schedule I under the Controlled Substances Act. Schedule I research requires DEA Schedule I registration (6-24 month approval), a DEA-approved API supplier (NIDA, Onyx Scientific, PsyGen, Filament Health, Usona Institute for research-grade), Schedule I-registered storage and chain-of-custody, and typically a concurrent FDA IND. Ketamine is Schedule III (Spravato / esketamine FDA-approved 2019) and does not face Schedule I constraints — which is why ketamine clinics scaled first. Investors expect explicit DEA and FDA regulatory pathway planning with 12-24 month regulatory runway budgeted before first patient dose.
Are Oregon Measure 109, Colorado Prop 122, and Australia TGA programs a real fundraising path?
State and country-level authorized programs are viable near-term revenue but not a substitute for FDA drug approval. Oregon Measure 109 (psilocybin services since January 2023) has approximately 30 licensed service centers, cash-pay only at $1,500-3,500 per session, and slower adoption than projected. Colorado Prop 122 (natural medicine health-hubs launched 2024-2025). Australia TGA authorized prescriber pathway (world-first since July 2023) allows TGA-authorized psychiatrists to prescribe MDMA for PTSD and psilocybin for TRD with high provider bar (Section 19 approval) and AUD $10,000-25,000 per treatment course. These are lower-scale, cash-pay-only, jurisdiction-limited programs — model as near-term revenue supplement, not as substitute for FDA approval.
What lessons does the 2023 ketamine-clinic collapse hold for psychedelics fundraising?
Field Trip Health filed CCAA bankruptcy protection in Canada in 2023. Ketamine Wellness Centers filed Chapter 11 in 2023. Mindbloom raised a down-round and pivoted. Nue Life pivoted. Ketamine-clinic unit economics broke on high real-estate and clinician cost per session, low session frequency (2-6 sessions per patient), insurance-coverage friction (most self-pay), and competition from at-home ketamine providers (Mindbloom, Better U, Peak). Investors underwrite psychedelics-clinic models with skepticism post-2023 — model conservative unit economics with realistic clinician cost, session frequency, and payer mix. Do not repeat Field Trip's real-estate-heavy multi-city expansion pre-unit-economics-proof.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database